Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

333
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
333
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

66.8K
Overview
66.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

468
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
468
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Premeal insulin administration lowers postprandial blood glucose and increases myocardial microvascular blood flow in people with type 1 diabetes: a randomised, crossover clinical trial.

Diabetologia·2026
Same author

Addressing barriers to care: A proposed model to predict prolonged treatment time among patients with locally advanced cervical cancer.

Brachytherapy·2026
Same author

Bridging community and facility care: cost-effectiveness of implementing 2019 childhood pneumonia management guidelines in India.

Cost effectiveness and resource allocation : C/E·2026
Same author

Training set augmentation and biology-aware harmonization improve radiomic models for lung cancer prediction in indeterminate nodules.

Scientific reports·2026
Same author

ABS/GEC-ESTRO objectives in training for vaginal cylinder brachytherapy.

Brachytherapy·2026
Same author

Finding a Balance: Auricular Acupressure in the Allergy Clinic.

The journal of allergy and clinical immunology. In practice·2026

Related Experiment Video

Updated: Jun 1, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

758

First Measurement: Proactive Immune Cell Sparing in Radiation Therapy.

Krishni Wijesooriya, Cam Nguyen, Mark R Conaway

    Medrxiv : the Preprint Server for Health Sciences
    |January 20, 2025
    PubMed
    Summary
    This summary is machine-generated.

    Sparing radiation dose to immune organs reduces radiation-induced immunosuppression (RIIS) in lung cancer patients. This optimized approach may enhance anti-tumor immunity and improve survival outcomes compared to standard treatment.

    More Related Videos

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
    09:01

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

    Published on: March 7, 2025

    277
    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
    06:20

    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

    Published on: March 11, 2021

    7.2K

    Related Experiment Videos

    Last Updated: Jun 1, 2025

    Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
    05:39

    Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

    Published on: April 5, 2024

    758
    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
    09:01

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

    Published on: March 7, 2025

    277
    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
    06:20

    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

    Published on: March 11, 2021

    7.2K

    Area of Science:

    • Oncology
    • Immunology
    • Radiation Oncology

    Background:

    • Radiation therapy (RT) can stimulate anti-tumor T cells but also cause immunosuppression.
    • Radiation-induced immunosuppression (RIIS) can limit the effectiveness of RT.
    • The benefit of sparing RT dose to immune organs is not well-established.

    Purpose of the Study:

    • To evaluate the clinical advantages of proactively sparing RT dose to immune-rich organs.
    • To assess the impact of dose reduction to blood, bone marrow, and lymph nodes on RIIS.
    • To compare RIIS-optimized treatment with standard treatment in early-stage lung cancer patients.

    Main Methods:

    • A phase II randomized trial involving 51 early-stage lung cancer patients treated with SBRT.
    • Two arms: RIIS-optimized-treatment (dose reduction to immune organs) and standard-treatment.
    • Peripheral blood collected at baseline and at multiple time points post-treatment to assess Absolute Lymphocyte Count (ALC).

    Main Results:

    • The optimized arm showed significantly less ALC reduction post-SBRT compared to the standard arm (13.4% improvement, p=0.01).
    • Central tumors demonstrated a greater ALC improvement in the optimized arm (29.5% improvement, p=0.004).
    • Grade 3 lymphopenia was absent in the optimized arm, and a trend towards improved Event-Free Survival and Overall Survival was observed.

    Conclusions:

    • Reducing RT dose to immune-rich organs significantly mitigates RIIS.
    • This strategy holds potential for enhancing immune-mediated anti-tumor activity.
    • Optimized RT planning may improve clinical outcomes in lung cancer patients.